The ‘Typically ≥99%’ Label: What to Confirm Before It Enters Your Methods Section

Methods-writing weeks have a habit of exposing every loose phrase in a draft, and supplier purity lines are among the most persistent offenders. A statement such as typically ≥99% (HPLC tested) looks precise enough to copy straight into a materials table, but it is a summary rather than a specification. It describes what a supplier generally expects across batches; it does not tell you what the vial in front of you contains, how the figure was generated, or whether a different laboratory running a different method would arrive at the same number. The useful question during a drafting week is not whether 99% sounds high enough, but what exactly is being claimed, and where is it documented.

What the ‘Typically ≥99%’ Figure Actually Describes

The word typically is doing a great deal of work in that sentence. It signals a distribution across batches rather than a per-vial guarantee, and it invites a follow-up question: is this a rolling average, a release criterion applied to every lot, or simply shorthand for the batches the supplier has handled most recently? The answer determines whether the number can appear in a methods section at all. As a rule, a materials table should cite the value reported on the certificate of analysis for the specific batch you used, with the certificate date given as a month and year, rather than a catalogue-level phrase that may not correspond to your delivery.

Second, the figure is method-bound. HPLC purity expressed as area percentage depends on column chemistry, mobile phase composition, gradient shape, detection wavelength, integration parameters and the peak-area threshold below which small signals are disregarded. Two laboratories can legitimately report different purity values for the same material and both be correct within their own conditions. If a certificate describes the method used, note it or reference it; if it does not, resist the temptation to imply that you replicated the supplier’s separation. Writing “purity as reported by the supplier” is honest and defensible; writing “purity confirmed in-house” when you have not run the assay is not.

Third, and most often overlooked, area percentage is not content. Peptides are supplied as lyophilised powders and, as the supplier’s own FAQs describe, contain trace amounts of mannitol as an excipient used to support stability during lyophilisation and solubility in storage. A purity percentage describes the proportion of integrated peak area attributable to the main peak, not the mass fraction of peptide in the vial. For in-vitro work this matters when you calculate nominal concentrations for an assay: two vials with the same reported purity can deliver slightly different amounts of material. Counter-ions, residual water and residual solvents all sit in the same gap between purity and mass.

Fourth, purity is not identity. A single clean peak demonstrates the absence of detectable related substances under those conditions; it does not prove the peak corresponds to the intended sequence. The shop states that each compound includes a certificate covering purity and identity by HPLC. Confirm what the document for your batch actually reports rather than assuming a mass confirmation, amino acid analysis or sequencing result is included.

Documentation Checks That Belong in the Methods Folder

Start with the certificate that accompanies the exact batch. Vial labels use a reference format that combines the SKU code and the expiry date, for example BPC10-03/27, and that reference links to the corresponding certificate. Quote it whenever you contact the supplier about documentation, and record it in the notebook alongside the assay date. This single habit resolves most later queries about which document applies to which vial.

Be careful with restocks. The FAQs note that restocked products may carry the same Internal Test Reference as earlier stock, and that an ITR links to associated sample testing reports — it does not confirm that separate deliveries come from the same production lot or that they have been independently tested separately. The practical consequence for a methods folder is straightforward: a certificate filed eighteen months ago should not be assumed to cover a recent delivery. Request the document that travels with the vial and re-file it.

Then check what the certificate actually covers. The site describes full-spectrum testing — purity, identity, heavy metals and endotoxin evaluation of submitted samples — as part of an expanded framework, and the homepage lists “CoAs Janoshik Analytical Reports”. Whether every certificate for every line reports every panel is something to confirm rather than infer; the live site and the batch document are the references, and any headline wording such as “≥99% Verified Purity” should be reconfirmed there. If your assay is sensitive to endotoxin or to metal carryover, ask the question specifically rather than relying on a general statement.

Physical checks deserve a line in the same note. Cap colour and other packaging details are not indicators of identity, analytical quality or manufacturing origin, and they may vary between deliveries. Record the form of the material, the storage instruction and the expiry date, and keep the storage record consistent with the supplier’s guidance: lyophilised material at −20°C or below, sealed with desiccant and protected from moisture, heat and light, with repeated freeze–thaw cycles avoided.

Turning the Confirmation into Protocol Language

A defensible materials statement names the supplier, the catalogue code, the label reference, the certificate date as a month and year, the purity value as reported on that certificate, and the method as the certificate describes it. Add the research-use-only framing in the same paragraph, because it governs everything downstream: products are labelled “For Research Use Only – Not for Human Consumption”, they are not for human or veterinary use, and the purchaser is responsible for lawful use, safe handling, storage and disposal, including compliance with COSHH and relevant UK laboratory safety standards.

Where the protocol describes preparation, keep the language inside an in-vitro workflow. That means allowing the vial and diluent to reach ambient temperature before opening, recording the diluent volume and the resulting concentration required for the assay, and aliquoting to avoid repeated freeze–thaw. Reconstituted material is less stable and should be held at 2–8°C for short-term laboratory use only. The supplier’s reconstitution calculator is a laboratory aid; it is not for medical or clinical use, and no part of the preparation should be described in dosing terms. If you are building a shortlist before a method is locked, read the individual product page and its certificate rather than the headline claim, and check that documentation before you Buy peptides for an assay that depends on a specific purity figure.

Two further drafting points are worth folding into the note. First, the shop does not supply blended peptides and recommends sourcing compounds individually and combining them only within a controlled experimental design — so a method requiring two materials should reference two catalogue codes and two certificates, not a single blended line. Second, fulfilment wording should stay out of the methods section entirely. Published terms describe next-working-day dispatch with tracked delivery, and the homepage “24hr UK Delivery” line is marketing language rather than a guaranteed arrival time; delivery estimates belong in a procurement note, not in an experimental protocol.

Finally, keep the audit trail explicit. A short paragraph stating where the certificates are archived, how restocks are flagged when an ITR is shared with earlier stock, and who re-verifies the document on receipt will save considerable time at review. Where a restocked vial arrives with unchanged documentation, note the reference and the date of the check, confirm whether the accompanying report corresponds to the current delivery, and file the confirmation beside the assay record so that the purity figure in the draft can be traced, months later, to a single named batch document.